Challenges in Benefit/Risk Appraisal

  • W. W. Lowrance
Conference paper
Part of the Health Systems Research book series (HEALTH)


The essential issue for any drug is: How much side-effect risk should be judged acceptable, for how much therapeutic benefit? Manufacturers must take benefit/risk considerations into account as they develop drugs and bring them into market, and iteratively, then, as they refine and shepherd the drugs through their commercial lifespans. Regulators must do the same as they control the admission of drugs into the market and guide refinements (such as reformulation, setting of indications and restrictions, provision of information to users, and so on). Obviously, physicians and other health-care providers and payers must also do so. All of these authorities must consider technical, personal, and social factors, and should think and act throughout in the interest of the ultimate public consumers of the drugs. Because I believe that continuity should be fostered among RAD-AR efforts, and because what I presented at the 1988 Wolfsberg conference [1] is still valid, I will briefly state my core concerns as I have articulated them before.


Fire Protection Disaster Preparedness Risk Appraisal Therapeutic Risk Fatal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lowrance WW (1989) A broad framework for confronting health risks. In: Horisberger B, Dinkel R (eds) The perception and management of drug safety risks. Springer, Berlin Heidelberg New York Tokyo, pp. 9–18Google Scholar
  2. 2.
    Burley D, Inman WHW (eds) (1988) Therapeutic risk. Wiley, ChichesterGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • W. W. Lowrance

There are no affiliations available

Personalised recommendations